Oruka Therapeutics (NASDAQ:ORKA) Trading Down 8.3% – Should You Sell?

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s share price dropped 8.3% on Monday . The company traded as low as $25.30 and last traded at $25.9220. Approximately 145,550 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 274,525 shares. The stock had previously closed at $28.27.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ORKA shares. Piper Sandler initiated coverage on Oruka Therapeutics in a report on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price objective on the stock. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a research report on Thursday, November 13th. They issued a “buy” rating and a $45.00 price objective for the company. BTIG Research raised their target price on shares of Oruka Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Finally, Barclays initiated coverage on Oruka Therapeutics in a research report on Monday, October 13th. They issued an “overweight” rating and a $48.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $48.88.

Oruka Therapeutics Price Performance

The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -14.04 and a beta of -0.39. The stock’s fifty day simple moving average is $29.21 and its two-hundred day simple moving average is $20.92.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.01. On average, sell-side analysts predict that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Insider Activity at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction on Friday, December 19th. The stock was sold at an average price of $30.61, for a total transaction of $214,270.00. Following the transaction, the insider owned 1,518 shares in the company, valued at approximately $46,465.98. The trade was a 82.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 24.69% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Viking Global Investors LP purchased a new position in shares of Oruka Therapeutics during the 3rd quarter valued at $51,280,000. Avoro Capital Advisors LLC acquired a new position in Oruka Therapeutics in the 3rd quarter worth about $25,640,000. Deep Track Capital LP raised its stake in shares of Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after purchasing an additional 735,983 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Oruka Therapeutics by 100.6% during the 2nd quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock valued at $7,932,000 after buying an additional 354,821 shares during the last quarter. Finally, Commodore Capital LP increased its holdings in Oruka Therapeutics by 23.5% in the third quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock worth $33,711,000 after buying an additional 333,340 shares during the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.